Differences_NN
between_PIN
United_NN
Kingdom_NN
and_PHC
United_NN
States_NN
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
Profit_NN
and_PHC
loss_NN
account_NN
Adjustments_NOMZ
to_PIN
the_DT
loss_NN
for_PIN
the_DT
period_NN
under_IN
UK_NN
GAAP_NN
and_CC
the_DT
net_JJ
profit_NN
under_IN
US_FPP1
GAAP_NN
are_VPRT
as_IN
follows_VPRT
:_:
Notes_NN
2003_CD
2002_CD
Loss_NN
for_PIN
the_DT
period_NN
under_IN
UK_NN
GAAP_NN
53.9_CD
45.8_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Revenue_NN
recognition_NOMZ
i_FPP1
27.3_CD
12.7_CD
Medeva_NN
goodwill_NN
adjustments_NOMZ
ii_VPRT
20.1_CD
3.6_CD
Amortisation_NOMZ
of_PIN
goodwill_NN
and_CC
other_JJ
intangibles_NN
iii_FW
64.2_CD
39.8_CD
Pension_NN
costs_VPRT
0.6_CD
1.9_CD
Stock-based_JJ
compensation_NOMZ
iv_NN
0.9_CD
7.2_CD
OGS_NN
acquisition_NOMZ
in_PIN
process_NN
research_NN
and_PHC
development_NOMZ
v_NN
2.3_CD
OGS_NN
acquisition_NOMZ
other_JJ
vi_FW
3.6_CD
Exceptional_JJ
items_NN
vii_FW
4.4_CD
Unrealised_JJ
gains_NN
on_PIN
derivative_JJ
financial_JJ
instruments_NOMZ
viii_FW
3.0_CD
6.9_CD
Deferred_VBN
taxation_NOMZ
ix_NN
4.7_CD
5.1_CD
Taxation_NOMZ
on_PIN
GAAP_NN
difference_NN
0.8_CD
Net_JJ
profit_NN
as_IN
adjusted_VBN
to_TO
accord_VB
with_PIN
US_FPP1
GAAP_NN
6.0_CD
15.2_CD
Shareholders_NN
funds_NN
Adjustments_NOMZ
between_PIN
shareholders_NN
funds_NN
under_IN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
are_VPRT
as_IN
follows_VPRT
:_:
Notes_NN
2003_CD
2002_CD
Shareholders_NN
funds_NN
under_IN
UK_NN
GAAP_NN
505.9_CD
564.4_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Revenue_NN
recognition_NOMZ
i_FPP1
1.5_CD
25.8_CD
Goodwill_NN
and_PHC
intangibles_NN
iii_FW
180.9_CD
163.2_CD
OGS_NN
acquisition_NOMZ
other_JJ
vi_NN
2.2_CD
Pensions_NN
0.4_CD
0.2_CD
Pensions_NN
other_JJ
comprehensive_JJ
income_NN
xi_FW
21.0_CD
14.0_CD
Unrealised_JJ
gains_NN
on_PIN
derivative_JJ
financial_JJ
instruments_NOMZ
viii_VPRT
5.8_CD
8.8_CD
Employee_NN
Share_NN
Ownership_NN
Plan_NN
x_SYM
1.7_CD
0.3_CD
Exceptional_JJ
items_NN
vii_FW
4.4_CD
Deferred_JJ
taxation_NOMZ
ix_NN
4.7_CD
Taxation_NOMZ
0.8_CD
Shareholders_NN
funds_NN
as_IN
adjusted_VBN
to_TO
accord_VB
with_PIN
US_FPP1
GAAP_NN
672.1_CD
696.5_CD
82_CD
Celltech_NN
Annual_JJ
Report_NN
2003_CD
Notes_NN
:_:
i_FPP1
Revenue_NN
recognition_NOMZ
Under_IN
UK_NN
GAAP_NN
,_,
non-refundable_JJ
licence_NN
fee_NN
revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
earned_VBN
._.
Refundable_JJ
licence_NN
fees_NN
are_VPRT [PASS]
deferred_VBN
until_IN
such_JJ
time_NN
as_IN
they_TPP3
are_VPRT
no_RB
longer_RB
refundable_JJ
._.
Arrangements_NOMZ
with_PIN
multiple_JJ
deliverables_NN
are_VPRT [PASS]
evaluated_VBN
and_ANDC
if_COND
the_DT
elements_NOMZ
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
to_TO
be_VB [BEMA]
separable_PRED
,_,
these_DEMO
elements_NOMZ
,_,
such_JJ
as_IN
milestones_NN
and_PHC
research_NN
and_PHC
development_NOMZ
contributions_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
separately_RB
based_VBN
on_PIN
the_DT
revenue_NN
recognition_NOMZ
criteria_NN
set_VBN [WZPAST]
out_PIN
in_PIN
note_NN
1_CD
to_PIN
the_DT
accounts_NN
._.
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
in_PIN
most_EMPH
circumstances_NN
the_DT
deferral_NN
of_PIN
non-refundable_JJ
upfront_JJ
licence_NN
fees_NN
and_CC
other_JJ
income_NN
received_VBN
under_IN
a_DT
contract_NN
where_RB
there_EX
is_VPRT
a_DT
continuing_VBG
involvement_NOMZ
with_PIN
the_DT
licensed_JJ
asset_NN
through_PIN
collaboration_NOMZ
or_CC
other_JJ
arrangements_NOMZ
._.
During_PIN
the_DT
year_NN
Pfizer_NN
terminated_VBD
its_PIT
relationship_NN
on_PIN
CDP870_CD
with_PIN
Celltech_NN
._.
Income_NN
previously_TIME
deferred_VBN
under_IN
US_FPP1
GAAP_NN
has_VPRT [SPAU] [PEAS]
consequently_CONJ
been_VBN [PASS]
released_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
ii_FW
Medeva_FW
goodwill_NN
adjustments_NOMZ
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
time_NN
frame_NN
allowed_VBN [SUAV]
to_TO
make_VB
adjustments_NOMZ
to_PIN
goodwill_NN
is_VPRT [BEMA]
one_CD
year_NN
from_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
,_,
except_PIN
for_PIN
adjustments_NOMZ
in_PIN
respect_NN
of_PIN
taxation_NOMZ
when_RB
an_DT
indefinite_JJ
period_NN
is_VPRT [BEMA]
available_PRED
._.
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
time_NN
frame_NN
available_JJ
extends_VPRT
to_PIN
the_DT
first_JJ
full_JJ
reporting_GER
period_NN
after_IN
the_DT
reporting_GER
period_NN
in_PIN
which_WDT [PIRE]
the_DT
acquisition_NOMZ
was_VBD [PASS]
made_VBN
._.
The_DT
2003_CD
adjustment_NOMZ
is_VPRT [BEMA]
in_PIN
respect_NN
of_PIN
the_DT
settlement_NOMZ
of_PIN
certain_JJ
tax_NN
exposures_NN
._.
After_IN
the_DT
look-back_JJ
period_NN
,_,
under_IN
UK_NN
GAAP_NN
,_,
potential_JJ
tax_NN
liabilities_NOMZ
that_TSUB
are_VPRT [PASS]
recorded_VBN
at_PIN
acquisition_NOMZ
and_CC
are_VPRT [SPAU] [PASS]
subsequently_TIME
released_VBN
are_VPRT [PASS]
recorded_VBN
as_IN
an_DT
income_NN
tax_NN
benefit_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
release_NN
of_PIN
the_DT
tax_NN
liability_NOMZ
is_VPRT [PASS]
recorded_VBN
as_IN
an_DT
adjustment_NOMZ
to_PIN
goodwill_NN
._.
iii_FW
Amortisation_NOMZ
of_PIN
goodwill_NN
and_CC
other_JJ
intangibles_NN
Under_IN
US_FPP1
GAAP_NN
the_DT
merger_NN
between_PIN
Celltech_NN
and_PHC
Chiroscience_NN
failed_VBD
to_TO
qualify_VB
as_IN
a_DT
pooling_VBG
of_PIN
interest_NN
and_ANDC
therefore_CONJ
additional_JJ
goodwill_NN
and_CC
intangible_JJ
assets_NN
were_VBD [PASS]
established_VBN [PRIV]
on_PIN
the_DT
US_FPP1
balance_NN
sheet_NN
certain_JJ
other_JJ
differences_NN
also_RB
arose_VBD
on_PIN
the_DT
acquisitions_NOMZ
of_PIN
Medeva_NN
and_PHC
OGS_NN
._.
In_CONJ
addition_NULL
,_,
amortisation_NOMZ
is_VPRT
no_RB
longer_RB
automatically_RB
charged_VBN
under_IN
SFAS_NN
142_CD
,_,
Goodwill_NN
and_CC
Other_JJ
Intangible_NN
Assets_NN
,_,
on_PIN
goodwill_NN
._.
Amortisation_NOMZ
continues_VPRT
to_TO
be_VB [PASS]
applied_VBN
in_PIN
the_DT
US_FPP1
on_PIN
finite_JJ
life_NN
intangibles_NN
._.
Goodwill_NN
and_PHC
infinite_NN
lived_VBD
intangible_JJ
assets_NN
are_VPRT [PASS]
tested_VBN
for_PIN
impairment_NOMZ
annually_RB
or_CC
when_RB
events_NN
indicate_VPRT [PRIV]
that_THVC
assets_NN
may_POMD
be_VB [PASS]
impaired_VBN
._.
iv_NN
Stock_NN
based_VBN
compensation_NOMZ
Under_IN
UK_NN
GAAP_NN
,_,
no_SYNE
compensation_NOMZ
expense_NN
is_VPRT [PASS]
recorded_VBN
in_PIN
connection_NOMZ
with_PIN
the_DT
issue_NN
of_PIN
share_NN
options_NOMZ
to_PIN
Group_NN
employees_NN
at_PIN
market_NN
value_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
APB_NN
25_CD
,_,
an_DT
annual_JJ
compensation_NOMZ
expense_NN
is_VPRT [BEMA]
imputed_PRED
for_PIN
stock_NN
compensation_NOMZ
arrangements_NOMZ
based_VBN [WZPAST]
on_PIN
the_DT
excess_NN
of_PIN
the_DT
market_NN
price_NN
over_IN
the_DT
exercise_NN
price_NN
at_PIN
the_DT
measurement_NOMZ
date_NN
._.
v_FW
OGS_FW
acquisition_NOMZ
in_PIN
process_NN
research_NN
and_PHC
development_NOMZ
Under_IN
US_FPP1
GAAP_NN
,_,
purchase_NN
accounting_GER
a_DT
fair_JJ
value_NN
exercise_NN
is_VPRT [PASS]
performed_VBN
to_TO
identify_VB
in_PIN
process_NN
research_NN
and_PHC
development_NOMZ
in_PIN
an_DT
acquired_VBN
company_NN
._.
The_DT
purchased_VBN
in_PIN
process_NN
research_NN
and_PHC
development_NOMZ
,_,
once_TIME
valued_VBN
,_,
is_VPRT [SPAU] [PASS]
immediately_TIME
expensed_VBN
._.
The_DT
in_PIN
process_NN
research_NN
and_PHC
development_NOMZ
determined_VBN [SUAV] [PRIV] [WZPAST]
in_PIN
the_DT
preliminary_JJ
purchase_NN
price_NN
allocation_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
reduced_VBN
to_PIN
the_DT
extent_NN
that_TOBJ
negative_JJ
goodwill_NN
was_VBD [PASS]
identified_VBN
._.
vi_FW
OGS_FW
acquisition_NOMZ
other_JJ
Under_IN
UK_NN
GAAP_NN
,_,
certain_JJ
businesses_NOMZ
acquired_VBN [WZPAST]
with_PIN
OGS_NN
were_VBD [PASS]
held_VBN [PRIV]
for_PIN
immediate_JJ
resale_NN
._.
Provision_NN
for_PIN
the_DT
result_NN
of_PIN
these_DEMO
businesses_NOMZ
notably_RB
proteomics_NN
and_PHC
Confirmant_NN
was_VBD [PASS]
made_VBN
in_PIN
the_DT
opening_GER
balance_NN
sheet_NN
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
results_NN
of_PIN
the_DT
businesses_NOMZ
post-acquisition_NOMZ
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
In_CONJ
addition_NULL
,_,
US_FPP1
GAAP_NN
and_PHC
UK_NN
GAAP_NN
differ_VPRT
in_PIN
the_DT
timing_NN
of_PIN
the_DT
recognition_NOMZ
of_PIN
certain_JJ
provisions_NN
and_PHC
closure_NN
costs_NN
._.
vii_FW
Exceptional_JJ
items_NN
US_FPP1
GAAP_NN
and_PHC
UK_NN
GAAP_NN
differ_VPRT
in_PIN
the_DT
timing_NN
of_PIN
the_DT
recognition_NOMZ
of_PIN
certain_JJ
redundancy_NN
arrangements_NOMZ
and_CC
other_JJ
closure_NN
costs_NN
._.
viii_FW
Unrealised_JJ
gains_NN
on_PIN
derivative_JJ
financial_JJ
instruments_NOMZ
As_IN
described_VBN
in_PIN
note_NN
1_CD
to_PIN
the_DT
accounts_NN
Financial_JJ
Instruments_NOMZ
the_DT
Group_NN
uses_VPRT
forward_RB
exchange_NN
contracts_NN
to_TO
match_VB
against_PIN
forecast_NN
receipts_NN
and_PHC
payments_NOMZ
in_PIN
foreign_JJ
currency_NN
._.
As_IN
the_DT
contracts_NN
are_VPRT [PASS]
not_XX0
matched_VBN
to_PIN
specific_JJ
receivables_NN
or_CC
payables_NN
the_DT
gains_NN
or_CC
losses_NN
arising_VBG [WZPRES]
on_PIN
the_DT
hedges_NN
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
until_IN
such_JJ
time_NN
as_IN
they_TPP3
are_VPRT [PASS]
realized_VBN [PRIV]
under_IN
UK_NN
GAAP_NN
._.
SFAS_NN
133_CD
determines_VPRT [SUAV] [PRIV]
that_THVC
under_IN
such_JJ
circumstances_NN
recognition_NOMZ
should_NEMD
be_VB [PASS]
made_VBN
currently_RB
of_PIN
the_DT
gains_NN
or_CC
losses_NN
that_TSUB
have_VPRT [PEAS]
arisen_VBN
and_CC
should_NEMD
be_VB [PASS]
taken_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
ix_FW
Deferred_JJ
taxation_NOMZ
UK_NN
GAAP_NN
,_,
FRS_NN
19_CD
,_,
requires_VPRT [SUAV]
that_THVC
the_DT
Group_NN
recognize_VPRT [PRIV]
deferred_JJ
tax_NN
assets_NN
in_PIN
respect_NN
of_PIN
timing_NN
differences_NN
associated_VBN [WZPAST]
with_PIN
goodwill_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
no_SYNE
deferred_JJ
tax_NN
liability_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
the_DT
difference_NN
between_PIN
the_DT
financial_JJ
carrying_GER
value_NN
and_CC
the_DT
tax_NN
basis_NN
of_PIN
recorded_VBN
goodwill_NN
for_PIN
which_WDT [PIRE]
amortisation_NOMZ
is_VPRT [PASS]
not_XX0
deducted_VBN
for_PIN
tax_NN
purposes_NN
._.
x_LS
Employee_NN
Share_NN
Ownership_NN
Plan_NN
ESOP_NN
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
Company_NN
's_POS
own_JJ
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOP_NN
are_VPRT [PASS]
recorded_VBN
as_IN
fixed_JJ
asset_NN
investments_NOMZ
at_PIN
cost_NN
._.
Under_IN
US_FPP1
GAAP_NN
those_DEMO
shares_NN
not_XX0
fully_AMP
vested_VBN
are_VPRT [PASS]
regarded_VBN
as_IN
treasury_NN
stock_NN
and_CC
recorded_VBN
at_PIN
cost_NN
as_IN
a_DT
deduction_NOMZ
from_PIN
shareholders_NN
'_POS
equity_NOMZ
._.
xi_FW
Pensions_NN
-_:
other_JJ
comprehensive_JJ
income_NN
Under_IN
US_FPP1
GAAP_NN
,_,
an_DT
additional_JJ
minimum_NN
pension_NN
liability_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
through_PIN
other_JJ
comprehensive_JJ
income_NN
in_PIN
certain_JJ
circumstances_NN
when_RB
there_EX
is_VPRT
a_DT
deficit_NN
of_PIN
plan_NN
assets_NN
relative_JJ
to_PIN
the_DT
accumulated_VBN
benefits_NN
obligation_NOMZ
._.
Under_IN
UK_NN
GAAP_NN
,_,
SSAP_NN
24_CD
,_,
there_EX
is_VPRT
no_SYNE
such_JJ
requirement_NOMZ
._.
